Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 3/2014

01-06-2014 | Research Article

Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055

Authors: Heather G. Keen, Sally-Ann Ricketts, Juliana Maynard, Armelle Logie, Rajesh Odedra, Aoife M. Shannon, Stephen R. Wedge, Sylvie M Guichard

Published in: Molecular Imaging and Biology | Issue 3/2014

Login to get access

Abstract

Purpose

The mTOR kinase inhibitor AZD8055 inhibits both mTORC1 and mTORC2 leading to disruption of glucose metabolism and proliferation pathways. This study assessed the impact of single and multiple doses of AZD8055 on the uptake of the glucose metabolism marker 2-deoxy-2-[18 F]fluoro-d-glucose ([18 F]FDG) and the proliferation marker 3′-deoxy-3′-[18 F]fluorothymidine ([18 F]FLT) in U87-MG glioma xenografts.

Procedures

Mice bearing U87-MG tumours received either vehicle or AZD8055 (20 mg/kg) once daily p.o. Mice were imaged with either [18 F]FDG or [18 F]FLT PET to assess treatment response. Comparisons were made between in vivo imaging and ex vivo histopathology data.

Results

Tumour uptake of [18 F]FDG was reduced by 33 % 1 h after a single dose of AZD8055 and by 49 % following 4 days of dosing. These changes coincided with suppression of the mTOR pathway biomarkers pS6 and pAKT. In contrast, the effect of AZD8055 on [18 F]FLT uptake was inconsistent.

Conclusions

The very rapid change in [18 F]FDG uptake following acute AZD8055 treatment suggests that this could be used as an early mechanistic biomarker of metabolic changes resulting from mTOR inhibition. The utility of [18 F]FLT for measuring the anti-proliferative effect of AZD8055 remains unclear.
Literature
1.
García-Martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375–385PubMedCrossRef
2.
O'Reilly KE, Rojo F, She QB et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508PubMedCentralPubMedCrossRef
3.
Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8PubMedCentralPubMedCrossRef
4.
Marshall G, Howard Z, Dry J et al (2011) Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. Biochem Soc Trans 39:456–459PubMedCrossRef
5.
Sylvie M, Guichard ZH et al (2012) AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer. Cancer Res 72(8):Suppl 1
6.
Smith GC, Ong WK, Rewcastle GW et al (2012) Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 442:161–169PubMedCentralPubMedCrossRef
7.
Eary JF, O’Sullivan F, Powitan Y, Chandhury KR et al (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 29:1149–1154PubMedCrossRef
8.
Weber WA. (2009) Assessing tumor response to therapy. J Nucl Med.;501S-10S.
9.
10.
Shinto A, Nair N, Dutt A, Baghel NS (2008) Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 33:486–487PubMedCrossRef
11.
Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122–127PubMedCrossRef
12.
Cejka D, Kuntner C, Preusser M et al (2009) FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. British J Cancer 2(100):1739–1745CrossRef
13.
Wei LH, Su H, Hildebrandt IJ et al (2008) Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14:3416–3426PubMedCrossRef
14.
Ma WW, Jacene H, Song D et al (2009) [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. Clin Oncol 1(27):2697–2704CrossRef
15.
Troost EG, Bussink J, Hoffmann AL et al (2010) 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 51:866–874PubMedCrossRef
16.
Solit D, Santos E, Pratilas DA et al (2007) 3-Deoxy-3-[18 F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF dependent tumors to MEK inhibition. Cancer Res 67:11463–11469PubMedCentralPubMedCrossRef
17.
Benz MR, Czernin J, Allen-Auerbach MS et al (2012) 3′-Deoxy-3′[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer 118:3135–3144PubMedCentralPubMedCrossRef
18.
Workman P, Twentyman P, Balkwill F et al (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (Second edition). Br J Cancer 77:1–10
19.
Keen H, Pichler B, Kukuk D et al (2012) An evaluation of 2-deoxy-2-[18F]fluoro-d-glucose and 3′-deoxy-3′-[18F]-fluorothymidine uptake in human tumor xenograft models. Mol Imaging Biol 14:355–365PubMedCrossRef
20.
Bao Q, Newport D, Chen M et al (2009) Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50:401–408PubMedCentralPubMedCrossRef
21.
Gambhir S. Quantitative assay development for PET. Chapter 2 in Phelps, Michael E (Ed.) PET: molecular imaging and its biological applications. Springer; 2004
22.
Chresta CM, Davies BR, Hickson I et al (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 1(70):288–298CrossRef
23.
Lee SC, Marzec M, Liu X et al (2012) Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma. NMR Biomed. doi:10.​1002/​nbm.​2825
24.
Nguyen QD, Perumal M, Waldman TA, Aboagye EO (2011) Glucose metabolism measured by [18F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol 4:241–248PubMedCentralPubMedCrossRef
25.
Aide N, Kinross K, Cullinane C et al (2010) 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med 51:1559–1564PubMedCrossRef
26.
27.
Soloviev D, Lewis D, Honess D, Aboagye E (2012) [18 F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48:416–424PubMedCrossRef
28.
29.
Waterton JC, Pylkkanen L (2012) Qualification of imaging biomarkers for oncology drug development. Eur J Cancer 48:409–415PubMedCrossRef
30.
Patlak CS, Blasberg RG (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5:584–590PubMedCrossRef
31.
Cheebsumon P, Velasquez LM, Hoekstra CJ et al (2011) Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38:832–842PubMedCentralPubMedCrossRef
32.
Maynard J, Ricketts SA, Gendrin C et al (2013) 2-Deoxy-2-[18 F]fluoro-d-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363. Mol Imaging Biol. Mol Imaging Biol 15:476–485PubMedCrossRef
33.
Schnell CR, Stauffer F, Allegrini PR et al (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68:6598–6607PubMedCrossRef
34.
35.
Guimaraes AR, Ross R, Figuereido JL et al (2011) MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. Mol Imaging Biol 13h:314–320CrossRef
Metadata
Title
Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055
Authors
Heather G. Keen
Sally-Ann Ricketts
Juliana Maynard
Armelle Logie
Rajesh Odedra
Aoife M. Shannon
Stephen R. Wedge
Sylvie M Guichard
Publication date
01-06-2014
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 3/2014
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-013-0705-0

Other articles of this Issue 3/2014

Molecular Imaging and Biology 3/2014 Go to the issue

Research Article

Sunitinib–CLIO Conjugate: A VEGFR/PDGFR-Targeting Active MR Probe

Research Article

6-[18F]Fluoro-l-DOPA Uptake in the Rat Pancreas is Dependent on the Tracer Metabolism

Research Article

Hybrid MicroPET Imaging for Dosimetric Applications in Mice: Improvement of Activity Quantification in Dynamic MicroPET Imaging for Accelerated Dosimetry Applied to 6-[18 F]Fluoro-l-DOPA and 2-[18 F]Fluoro-l-Tyrosine

Brief Article

Radiosynthesis of [124I]Iodometomidate and Biological Evaluation Using Small-Animal PET

Research Article

Evaluation of Rho-Kinase Activity in Mice Brain Using N-[11C]Methyl-hydroxyfasudil with Positron Emission Tomography

Research Article

Tumor Endothelial Marker Imaging in Melanomas Using Dual-Tracer Fluorescence Molecular Imaging